retatrutide clinical trial results 2024 VisualAbstract: reduces body weight by 17.5% in patients with obesity Lilly's 'triple G' agonist triumphs

Mitochondrial peptides modulate mitochondrial function during cellular senescence

What These Findings Mean for GLP-1 Drug Users The study demonstrates how artificial intelligence can help researchers better understand patient experiences with GLP-1 drugs

Exenatide: Least Effective Option Byetta, known by its generic name, Exenatide, is acknowledged as the GLP-1 receptor agonist with the lowest efficacy for aiding in weight loss

Where the Side Effect Profiles Differ While the overall GI side effect rates are comparable, a 2025 comparative safety analysis noted some differences: semaglutide was associated with slightly higher rates of vomiting, constipation, and gastroesophageal reflux (GERD), while tirzepatide showed marginally higher rates of nausea at the highest dose levels

Repeated stimulation of growth-hormone pathways may shift endocrine set points over months to years with unpredictable downstream consequences

Retatrutide (12mg): Up to 28.7% body weight reduction over 68 weeks in TRIUMPH-4